Angle PLC Prostate Cancer Update (9546A)
March 30 2017 - 2:01AM
UK Regulatory
TIDMAGL
RNS Number : 9546A
Angle PLC
30 March 2017
For immediate release 30 March 2017
ANGLE plc ("the Company")
POTENTIAL FOR PREDICTION OF METASTASIS IN PROSTATE CANCER
Barts Cancer Institute present new findings at World CDx Europe
2017 conference in London
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is delighted to announce that researchers from the Barts Cancer
Institute (BCI), Queen Mary University of London, have presented
new results at the World CDx Europe 2017 conference in London of
their work with ANGLE's Parsortix system in prostate cancer. The
new findings suggest a broader range of potential applications for
Parsortix in prostate cancer from early to late disease
prognosis.
Metastasis, the spread of cancer to another part of the body, is
responsible for over 90% of cancer-related deaths. Consequently, a
key issue in the treatment of prostate cancer is to determine
whether the cancer has been contained or whether it is continuing
to progress to metastasis. In the latter case, the earlier
treatment can be deployed the better.
BCI have now completed a pilot study in over 80 patients to
evaluate the capability of Parsortix to be used to identify whether
prostate cancer patients have progressed to metastasis. The results
presented today indicate that the use of Parsortix, in combination
with existing assessments, is potentially more effective than
existing parameters currently used to predict metastasis in
identifying those patients who have progressed to metastasis.
The gold standard for detecting metastasis is imaging. This
cannot be predictive as it is imaging metastatic sites that have
already developed. Utilising Parsortix it may be possible to
improve the prediction of the likely development of metastasis
early and/or to identify the presence of metastasis before it can
be seen by imaging technologies. This would benefit patients by
allowing early treatment and by reducing harmful exposure to
radioactive imaging.
The Parsortix analysis is based on analysis of mesenchymal CTCs,
which cannot be undertaken using alternative antibody-based systems
or by ctDNA analysis.
Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer
Institute, commented:
"Our latest results demonstrate the potential for the Parsortix
system to be used to identify patients with metastasis through a
simple blood test. This offers the potential for the prediction
and/or early detection of metastasis, which would meet a key need
in the treatment of prostate cancer, the most common cancer in
men."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is another significant milestone in progressing the
development of Parsortix for the treatment of prostate cancer. The
new results further support the expansion of the potential clinical
application to include both early and late stage prostate
cancer."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser),
Steve Cox
Russell Kerr (Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESUKOURBNAOUUR
(END) Dow Jones Newswires
March 30, 2017 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024